Nyxoah (NASDAQ:NYXH – Get Free Report) and Nanovibronix (NASDAQ:FEED – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitability.
Institutional and Insider Ownership
16.4% of Nanovibronix shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by insiders. Comparatively, 12.2% of Nanovibronix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Nyxoah and Nanovibronix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nyxoah | -443.16% | -178.90% | -81.83% |
| Nanovibronix | -1,093.61% | -60.73% | -48.48% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nyxoah | $11.33 million | 4.86 | -$101.92 million | ($2.52) | -0.56 |
| Nanovibronix | $1.93 million | 0.21 | -$18.18 million | ($117.28) | -0.00 |
Nanovibronix has lower revenue, but higher earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Nyxoah has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Nyxoah and Nanovibronix, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nyxoah | 1 | 1 | 2 | 0 | 2.25 |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
Nyxoah presently has a consensus target price of $4.26, suggesting a potential upside of 200.14%. Given Nyxoah’s stronger consensus rating and higher probable upside, analysts clearly believe Nyxoah is more favorable than Nanovibronix.
Summary
Nyxoah beats Nanovibronix on 9 of the 14 factors compared between the two stocks.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
